212 related articles for article (PubMed ID: 36599842)
1. The prevalence, presentation and outcome of colistin susceptible-only Acinetobacter Baumannii-associated pneumonia in intensive care unit: a multicenter observational study.
Wang SH; Yang KY; Sheu CC; Lin YC; Chan MC; Feng JY; Chen CM; Chen CY; Zheng ZR; Chou YC; Peng CK
Sci Rep; 2023 Jan; 13(1):140. PubMed ID: 36599842
[TBL] [Abstract][Full Text] [Related]
2. Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii.
Liang CA; Lin YC; Lu PL; Chen HC; Chang HL; Sheu CC
Clin Microbiol Infect; 2018 Aug; 24(8):908.e1-908.e7. PubMed ID: 29108947
[TBL] [Abstract][Full Text] [Related]
3. Carbapenem-resistant versus carbapenem-susceptible Acinetobacter baumannii bacteremia in a Greek intensive care unit: risk factors, clinical features and outcomes.
Routsi C; Pratikaki M; Platsouka E; Sotiropoulou C; Nanas S; Markaki V; Vrettou C; Paniara O; Giamarellou H; Roussos C
Infection; 2010 Jun; 38(3):173-80. PubMed ID: 20224962
[TBL] [Abstract][Full Text] [Related]
4. Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia.
Khawcharoenporn T; Pruetpongpun N; Tiamsak P; Rutchanawech S; Mundy LM; Apisarnthanarak A
Int J Antimicrob Agents; 2014 Apr; 43(4):378-82. PubMed ID: 24613422
[TBL] [Abstract][Full Text] [Related]
5. Risk factors of multidrug-resistant, extensively drug-resistant and pandrug-resistant Acinetobacter baumannii ventilator-associated pneumonia in a Medical Intensive Care Unit of University Hospital in Thailand.
Inchai J; Liwsrisakun C; Theerakittikul T; Chaiwarith R; Khositsakulchai W; Pothirat C
J Infect Chemother; 2015 Aug; 21(8):570-4. PubMed ID: 26026660
[TBL] [Abstract][Full Text] [Related]
6. Risk factors and outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia in the neonate: A case-case-control study.
Thatrimontrichai A; Techato C; Dissaneevate S; Janjindamai W; Maneenil G; Kritsaneepaiboon S; Tanaanantarak P
J Infect Chemother; 2016 Jul; 22(7):444-9. PubMed ID: 27229539
[TBL] [Abstract][Full Text] [Related]
7. Insights into the epidemiology, risk factors, and clinical outcomes of carbapenem-resistant
Zhang Y; Xu G; Miao F; Huang W; Wang H; Wang X
Front Public Health; 2023; 11():1282413. PubMed ID: 38098829
[TBL] [Abstract][Full Text] [Related]
8. Clinical effectiveness of cefiderocol for the treatment of bloodstream infections due to carbapenem-resistant Acinetobacter baumannii during the COVID-19 era: a single center, observational study.
Oliva A; Liguori L; Covino S; Petrucci F; Cogliati-Dezza F; Curtolo A; Savelloni G; Comi M; Sacco F; Ceccarelli G; Viscido A; Alessandri F; Raponi G; Pugliese F; Mastroianni CM; Venditti M
Eur J Clin Microbiol Infect Dis; 2024 Jun; 43(6):1149-1160. PubMed ID: 38634975
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of combination therapy with standard-dose carbapenem for treating nosocomial pneumonia caused by carbapenem-resistant Acinetobacter baumannii in intensive care units: A multicentre retrospective propensity score-matched study.
Wang SH; Yang KY; Sheu CC; Lin YC; Chan MC; Feng JY; Chen CM; Chen CY; Zheng ZR; Chou YC; Peng CK;
Int J Antimicrob Agents; 2024 Jan; 63(1):107044. PubMed ID: 38040319
[TBL] [Abstract][Full Text] [Related]
10. Ineffectiveness of colistin monotherapy in treating carbapenem-resistant Acinetobacter baumannii Pneumonia: A retrospective single-center cohort study.
Jeon CH; Kim SH; Kim HT; Park KJ; Wi YM
J Infect Public Health; 2024 May; 17(5):774-779. PubMed ID: 38518683
[TBL] [Abstract][Full Text] [Related]
11. Intravenous fosfomycin for treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii: A multi-centre clinical experience.
Russo A; Gullì SP; D'Avino A; Borrazzo C; Carannante N; Dezza FC; Covino S; Polistina G; Fiorentino G; Trecarichi EM; Mastroianni CM; Torti C; Oliva A
Int J Antimicrob Agents; 2024 Jul; 64(1):107190. PubMed ID: 38697579
[TBL] [Abstract][Full Text] [Related]
12. Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia.
Aydemir H; Akduman D; Piskin N; Comert F; Horuz E; Terzi A; Kokturk F; Ornek T; Celebi G
Epidemiol Infect; 2013 Jun; 141(6):1214-22. PubMed ID: 22954403
[TBL] [Abstract][Full Text] [Related]
13. Phenotypic and molecular characterization of Acinetobacter baumannii isolates causing lower respiratory infections among ICU patients.
Jain M; Sharma A; Sen MK; Rani V; Gaind R; Suri JC
Microb Pathog; 2019 Mar; 128():75-81. PubMed ID: 30562602
[TBL] [Abstract][Full Text] [Related]
14. Colistin alone or combined with sulbactam or carbapenem against A. baumannii in ventilator-associated pneumonia.
Yilmaz GR; Guven T; Guner R; Kocak Tufan Z; Izdes S; Tasyaran MA; Acikgoz ZC
J Infect Dev Ctries; 2015 May; 9(5):476-85. PubMed ID: 25989167
[TBL] [Abstract][Full Text] [Related]
15. Use of adjunctive aerosolized antimicrobial therapy in the treatment of Pseudomonas aeruginosa and Acinetobacter baumannii ventilator-associated pneumonia.
Arnold HM; Sawyer AM; Kollef MH
Respir Care; 2012 Aug; 57(8):1226-33. PubMed ID: 22349038
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of cefiderocol- vs colistin-containing regimen for treatment of bacteraemic ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii in patients with COVID-19.
Russo A; Bruni A; Gullì S; Borrazzo C; Quirino A; Lionello R; Serapide F; Garofalo E; Serraino R; Romeo F; Marascio N; Matera G; Longhini F; Trecarichi EM; Torti C
Int J Antimicrob Agents; 2023 Jul; 62(1):106825. PubMed ID: 37088438
[TBL] [Abstract][Full Text] [Related]
17. Mortality and ventilator dependence in critically ill patients with ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii.
Kao HH; Peng CK; Sheu CC; Lin YC; Chan MC; Wang SH; Chen CM; Shen YC; Zheng ZR; Lin YT; Hsu HS; Feng JY; Yang KY;
J Microbiol Immunol Infect; 2023 Aug; 56(4):822-832. PubMed ID: 37149411
[TBL] [Abstract][Full Text] [Related]
18. Management of ventilator associated pneumonia with a new antibiotic adjuvant entity (ceftriaxone+sulbactam+disodium edetate) - A novel approach to spare carbapenems.
Sathe P; Maddani S; Kulkarni S; Munshi N
J Crit Care; 2017 Oct; 41():145-149. PubMed ID: 28535440
[TBL] [Abstract][Full Text] [Related]
19. Acinetobacter baumannii ventilator-associated pneumonia: epidemiology, clinical characteristics, and prognosis factors.
Chaari A; Mnif B; Bahloul M; Mahjoubi F; Chtara K; Turki O; Gharbi N; Chelly H; Hammami A; Bouaziz M
Int J Infect Dis; 2013 Dec; 17(12):e1225-8. PubMed ID: 24094525
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Carbapenem-Resistant Acinetobacter baumannii Ventilator-Associated Pneumonia: Retrospective Comparison Between Intravenous Colistin and Intravenous Ampicillin-Sulbactam.
Zalts R; Neuberger A; Hussein K; Raz-Pasteur A; Geffen Y; Mashiach T; Finkelstein R
Am J Ther; 2016; 23(1):e78-85. PubMed ID: 24263165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
